SCHEMBL8437359

SCHEMBL8437359

Cc1ccc(-c2n[nH]c3ccc(-c4n[nH]c(CN5CCCC5)n4)cc23)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.71
DYRK1A Q13627 10/20 0.41
CLK2 P49760 9/20 0.41
CLK3 P49761 8/20 0.41
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
SIGMAR1 Q99720 1/20 0.38
JAK2 O60674 2/20 0.38
GAK O14976 1/20 0.38
DYRK3 O43781 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
NQO2 P16083 1/20 0.38
CSNK2A2 P19784 1/20 0.38
FECH P22830 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
CSNK1A1 P48729 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5379726 0.92 CSNK1D (0.74) CSNK1DDYRK1ACLK2CLK3SIGMAR1
SCHEMBL13049893 0.87 CSNK1D (0.80) CSNK1DDYRK1ACLK2CLK3WNT1
SCHEMBL5378193 0.87 CSNK1D (0.80) CSNK1DDYRK1ACLK2CLK3JAK2
SCHEMBL14578438 0.85 CSNK1D (0.67) CSNK1DDYRK1ACLK2CLK3JAK2
SCHEMBL5383762 0.85 CSNK1D (0.70) CSNK1DDYRK1ACLK2CLK3JAK2
SCHEMBL5387406 0.84 CSNK1D (0.82) CSNK1DDYRK1ACLK2CLK3JAK2
SCHEMBL4079762 0.83 CSNK1D (0.74) CSNK1DDYRK1ACLK2CLK3JAK2
SCHEMBL5296238 0.83 CSNK1D (1.00) CSNK1DDYRK1ACLK2CLK3WNT1
SCHEMBL14564654 0.82 CSNK1D (0.76) CSNK1DDYRK1ACLK2CLK3MAP4K4
SCHEMBL5383771 0.82 CSNK1D (0.98) CSNK1DDYRK1ACLK2CLK3WNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R CSNK1D 410/4885DYRK1A 426/4885CLK2 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.